Zidovudine Price Trend

Zidovudine Price Trend, Index and Forecast

Track the latest insights on zidovudine price trend and forecast with detailed analysis of regional fluctuations and market dynamics across North America, Latin America, Central Europe, Western Europe, Eastern Europe, Middle East, North Africa, West Africa, Central and Southern Africa, Central Asia, Southeast Asia, South Asia, East Asia, and Oceania.

Zidovudine Prices Outlook Q2 2025

• USA: US$ 619,463/MT             
• China: US$ 554,612/MT          
• Germany: US$ 639,246/MT    
• Netherlands: US$ 671,208/MT            
• Japan: US$ 593,435/MT

Zidovudine Price Chart

Get real-time access to monthly/quaterly/yearly prices, Request Sample

During the second quarter of 2025, the zidovudine prices in the USA reached 619,463 USD/MT in June. Zidovudine prices in the USA during this quarter were influenced by fluctuations in the cost of key intermediates imported from Asia. The pharmaceutical manufacturing sector experienced margin pressures due to rising energy and compliance costs. Demand from federal procurement programs remained steady, while distribution expenses increased amid limited container availability and labor-related delays in warehousing and last-mile logistics.

During the second quarter of 2025, zidovudine prices in China reached 554,612 USD/MT in June. In China, zidovudine prices were shaped by shifts in active pharmaceutical ingredient (API) production capacity due to environmental compliance inspections across Zhejiang and Jiangsu provinces. Feedstock costs increased amid higher solvent prices and energy tariffs. Export-oriented supply was affected by congestion at major ports, while demand from the domestic healthcare sector remained consistent due to public health initiatives.

During the second quarter of 2025, the zidovudine prices in Germany reached 639,246 USD/MT in June. Zidovudine pricing in Germany was impacted by elevated input costs driven by energy market volatility and imported API expenses. Production was constrained by disruptions in the supply of pharmaceutical-grade raw materials from non-EU sources. The healthcare sector’s procurement cycles remained stable, but regulatory adjustments in drug pricing frameworks introduced uncertainty in forecasting and inventory planning across distribution networks.

During the second quarter of 2025, the zidovudine prices in the Netherlands reached 671,208 USD/MT in June. In the Netherlands, zidovudine prices in this quarter were affected by supply chain interruptions linked to delayed shipments of Indian and Chinese APIs. The pharmaceutical sector encountered higher manufacturing overheads due to rising labor and utility costs. Demand from public hospitals and clinics remained unchanged, but parallel trade activity increased, influencing regional supply balances and purchase prices.

During the second quarter of 2025, the zidovudine prices in Japan reached 593,435 USD/MT in June. Japan’s zidovudine pricing was influenced by increased import costs of raw materials from China and India, coupled with currency depreciation against major trading currencies. The pharmaceutical sector faced tighter production margins due to high regulatory compliance costs and elevated utility tariffs. Demand from the national healthcare system remained steady, while port delays and domestic freight rate increases further affected distribution costs.

Zidovudine Prices Outlook Q2 2023

• USA: US$ 562535/MT
• China: US$ 503644/MT
• Germany: US$ 580500/MT

The price of zidovudine in the United States for Q2 2023 reached 562535 USD/MT in June. Whereas, the price of zidovudine in China for Q2 2023 reached 503644 USD/MT in June. Similarly, the price of zidovudine in Germany for Q2 2023 reached 580500 USD/MT in June.

Regional Coverage

The report provides a detailed analysis of the market across different regions, each with unique pricing dynamics influenced by localized market conditions, supply chain intricacies, and geopolitical factors. This includes price trends, price forecast and supply and demand trends for each region, along with spot prices by major ports. The report also provides coverage of FOB and CIF prices, as well as the key factors influencing the zidovudine prices.

Global Zidovudine Price Trend

The report offers a holistic view of the global zidovudine pricing trends in the form of zidovudine price charts, reflecting the worldwide interplay of supply-demand balances, international trade policies, and overarching economic factors that shape the market on a macro level. This comprehensive analysis not only highlights current price levels but also provides insights into historical price of zidovudine, enabling stakeholders to understand past fluctuations and their underlying causes. The report also delves into price forecast models, projecting future price movements based on a variety of indicators such as expected changes in supply chain dynamics, anticipated policy shifts, and emerging market trends. By examining these factors, the report equips industry participants with the necessary tools to make informed strategic decisions, manage risks, and capitalize on market opportunities. Furthermore, it includes a detailed zidovudine demand analysis, breaking down regional variations and identifying key drivers specific to each geographic market, thus offering a nuanced understanding of the global pricing landscape.

Europe Zidovudine Price Trend

Q2 2025:

As per the zidovudine price index, zidovudine prices in Europe during Q2 2025 were influenced by persistent supply disruptions of active pharmaceutical ingredients imported from Asia. The pharmaceutical manufacturing sector faced elevated production costs due to increased energy tariffs and strict regulatory compliance expenses. Delays in customs clearance and tighter parallel trade regulations further impacted regional supply flows. Stable demand from national healthcare systems sustained consistent procurement activity across member states.

Q2 2023:

European zidovudine prices are examined, highlighting the market-specific influences in the region, such as stringent environmental regulations, the competitive landscape, and import-export imbalances that significantly affect pricing structures.

This analysis can be extended to include detailed zidovudine price information for a comprehensive list of countries.

North America Zidovudine Price Trend

Q2 2025:

As per the zidovudine price index, in North America, zidovudine pricing was driven by fluctuations in import costs of key raw materials, particularly from Asia. The pharmaceutical sector experienced rising overheads linked to energy prices and labor constraints. Federal healthcare procurement schedules remained consistent, but distribution bottlenecks, including rail and trucking delays, affected delivery timelines. Additionally, inventory buildup strategies added temporary strain on short-term supply chains.

Q2 2023:

The analysis of zidovudine prices in North America delves into the regional industry dynamics, encompassing the impact of local production capacities and the trade flows between North America and other significant global markets.

Specific zidovudine historical data within the United States and Canada can also be provided.

Middle East and Africa Zidovudine Price Trend

Q2 2025:

As per the zidovudine price chart, the prices in the Middle East and Africa fluctuated due to a complex interplay of factors, primarily driven by supply chain disruptions, seasonal demand shifts, and geopolitical influences. A tight supply from refineries, exacerbated by maintenance rounds and unplanned outages, put pressure on prices. Simultaneously, demand from the agrochemical sector during the planting season contributed to price changes.

Q2 2023:

The report explores the zidovudine pricing trends in the Middle East and Africa, considering factors like regional industrial growth, the availability of natural resources, and geopolitical tensions that uniquely influence market prices.

In addition to region-wise data, information on zidovudine prices for countries can also be provided.

Asia Pacific Zidovudine Price Trend

Q2 2025:

Zidovudine prices in the Asia Pacific region were shaped by environmental compliance inspections across major production zones in China and India, which limited API output. The pharmaceutical manufacturing sector experienced higher input costs due to energy price adjustments and rising solvent rates. Regional demand from public health programs remained firm, while port congestion and intra-regional shipping delays added logistical challenges to supply continuity.

Q2 2023:

The zidovudine pricing trends in Asia Pacific are examined, reflecting the role of the region as a major global production hub and consumer market, with price dynamics heavily influenced by supply chain efficiencies, regional demand surges, and policy shifts in major economies.

This zidovudine price analysis can be expanded to include a comprehensive list of countries within the region.

Latin America Zidovudine Price Trend

Q2 2025:

Latin America's zidovudine market is predominantly influenced by its rich natural reserves, particularly in countries like Chile and Brazil. However, political instability and inconsistent regulatory frameworks can lead to significant volatility in zidovudine prices. Infrastructure challenges and logistical inefficiencies often impact the supply chain, affecting the region's ability to meet international demand consistently. Moreover, the zidovudine price index, economic fluctuations, and currency devaluation are critical factors that need to be considered when analyzing zidovudine pricing trends in this region.

Q2 2023:

The analysis of Zidovudine prices in Latin America provides a detailed overview, reflecting the unique market dynamics in the region influenced by economic policies, industrial growth, and trade frameworks.

This comprehensive review can be extended to include specific countries within the region.

Zidovudine Price Trend, Market Analysis, and News

IMARC's latest publication, “Zidovudine Prices, Trend, Chart, Demand, Market Analysis, News, Historical and Forecast Data Report 2025 Edition,” presents a detailed examination of the zidovudine market, providing insights into both global and regional trends that are shaping prices. This report delves into the spot price of zidovudine at major ports and analyzes the composition of prices, including FOB and CIF terms. It also presents detailed zidovudine prices trend analysis by region, covering North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The factors affecting zidovudine pricing, such as the dynamics of supply and demand, geopolitical influences, and sector-specific developments, are thoroughly explored. This comprehensive report helps stakeholders stay informed with the latest market news, regulatory updates, and technological progress, facilitating informed strategic decision-making and forecasting.

Zidovudine Market Analysis

The global zidovudine market size reached USD 1.15 Billion in 2024. By 2033​, IMARC Group expects the market to reach USD 1.76 Billion, at a projected CAGR of 4.56 % during 2025-2033.

• An important development in the zidovudine industry is the drug's growing uptake in low- and middle-income nations (LMICs). The World Health Organization (WHO) states that zidovudine is still an essential part of HIV therapy regimens, especially in regions with limited resources. The use of zidovudine in first- and second-line therapy choices is highlighted in the WHO's 2023 HIV treatment guidelines, particularly in cases where medication resistance has developed. Its established effectiveness and lower cost in comparison to more recent antiretroviral medications are the main reasons for its broad use. Zidovudine is now widely available in these areas’ thanks in large part to the Global Fund and PEPFAR (President's Emergency Plan for AIDS Relief), which have provided finance and assistance for the acquisition and distribution of the medication. Thus, zidovudine's demand in low- and middle-income countries (LMICs) keeps rising, indicating the drug's vital role in international efforts to treat HIV.
• There is a tendency in the zidovudine market toward the usage of combination therapies increasing. Zidovudine should be used in conjunction with other antiretrovirals, according to U.S. Department of Health and Human Services (HHS) guidelines, to improve treatment efficacy and lower the risk of drug resistance. Zidovudine-containing fixed-dose combos (FDCs), including Combivir (zidovudine plus lamivudine), are becoming increasingly widely used. Clinical research demonstrating that combination medicines enhance patient adherence and outcomes over monotherapy lends credence to this trend. The National Institutes of Health (NIH) has released new data that indicates combination medicines, such as zidovudine, have significantly reduced patients' HIV viral loads, improving their quality of life and lowering transmission rates.
• Another noteworthy development in the zidovudine market is the focus on cost-cutting and generic manufacture. As a result of patent expirations, a few generic producers have entered the market, bringing zidovudine's price down and increasing its accessibility to a wider range of people. U.S. Food and Drug Administration (FDA) has approved numerous generic zidovudine variants, ensuring a competitive market that benefits customers. The expansion of treatment coverage, particularly in marginalized regions, has been facilitated by the availability of reasonably priced generic zidovudine, according to data from the Centers for Disease Control and Prevention (CDC). In the context of global health campaigns, this trend is especially important because groups like UNAIDS and Médecins Sans Frontières (MSF) advocate for reduced drug costs to provide HIV treatment for all people. The emphasis on generic manufacture promotes ongoing innovation in the antiretroviral market in addition to providing cost-effective treatment.

Zidovudine News

The report covers the latest developments, updates, and trends impacting the global zidovudine industry, providing stakeholders with timely and relevant information. This segment covers a wide array of news items, including the inauguration of new production facilities, advancements in zidovudine production technologies, strategic market expansions by key industry players, and significant mergers and acquisitions that impact the zidovudine price trend.

Latest developments in the zidovudine industry:

• In 2024, Cipla partnered with CSIR-CDRI to advance ophthalmic antifungal treatments and formed a joint venture with Kemwell Biopharma and Manipal Education & Medical Group for cell therapy products. These collaborations aim to innovate and expand Cipla’s zidovudine market reach in critical therapeutic areas.
• In 2023, Cognizant announced an expansion of its relationship with Gilead Sciences. Gilead is a leading biopharmaceutical company advancing innovative medicines to prevent and treat life-threatening diseases. Gilead Sciences is focusing on technological advancements and strategic partnerships to enhance its zidovudine offerings. The company is leveraging AI and big data analytics to optimize its drug development and manufacturing processes.

Product Description

Zidovudine, commonly referred to as azidothymidine, or AZT, is a ground-breaking antiviral drug that is mostly used to treat and manage HIV/AIDS. Reverse transcriptase is an enzyme required for HIV replication, and as such, it functions as a nucleoside reverse transcriptase inhibitor (NRTI). Zidovudine efficiently stops the virus from multiplying and infecting healthy cells by integrating itself into the viral DNA.

As the first medication accessible for HIV treatment, zidovudine represented a historic milestone when it was originally approved by the FDA in 1987. To prevent HIV from being transferred from mother to child during childbirth, it is typically given orally as pills, capsules, or syrup. In more extreme circumstances, intravenous delivery of the medication may be necessary. To increase the effectiveness of highly active antiretroviral therapy (HAART), zidovudine is frequently used in combination with other antiretroviral medications.

Zidovudine has been mainly replaced by more recent antiretroviral drugs that have higher safety profiles and fewer side effects, but it is still an important choice, especially in situations where resources are scarce. Anemia, neutropenia, and gastrointestinal issues are typical adverse effects. Zidovudine continues to be used in some situations and has played a significant part in the history of HIV treatment, despite these difficulties, which highlights its continued significance in world health.

Report Coverage

Key Benefits for Stakeholders:

• IMARC’s report presents a detailed analysis of zidovudine pricing, covering global and regional trends, spot prices at key ports, and a breakdown of Ex Works, FOB, and CIF prices.
• The study examines factors affecting zidovudine price trend, including raw material costs, supply-demand shifts, geopolitical impacts, and industry developments, offering insights for informed decision-making.
• The competitive landscape review equips stakeholders with crucial insights into the latest market news, regulatory changes, and technological advancements, ensuring a well-rounded, strategic overview for forecasting and planning.
• IMARC offers various subscription options, including monthly, quarterly, and biannual updates, allowing clients to stay informed with the latest market trends, ongoing developments, and comprehensive market insights. The zidovudine price charts ensure our clients remain at the forefront of the industry.